胶质瘤起源于大脑中最常见的非神经元细胞（胶质细胞），是最常见的脑肿瘤，与高死亡率和不良预后相关。神经胶质瘤细胞表现出破坏正常细胞周期调节的倾向，导致异常增殖和恶性生长。本研究调查了GJC1在胶质瘤中的预测潜力，并探讨了其与细胞周期的关系。利用中国胶质瘤基因组图谱（CGGA）和癌症基因组图谱（TCGA）对RNA-seq和单细胞测序数据进行回顾性分析数据库。分析GJC1在不同病理特征的胶质瘤和不同非神经细胞群中的差异表达。使用基因集变异分析（GSVA）检查功能数据。此外，CellMiner 用于评估这些数据库中 GJC1 表达与预测治疗反应之间的关系。GJC1 表达在高级别胶质瘤和 1p/19q 非共缺失胶质瘤中富集。在 TCGA 神经胶质瘤亚型组内的经典亚型和间充质亚型中观察到 GJC1 富集。在单细胞亚组分析中，与其他非神经元细胞相比，胶质瘤组织中的 GJC1 表达较高。此外，神经胶质瘤细胞的 TCGA 经典亚型比其他亚组表现出更多的 GJC1 表达。 GJC1 成为神经胶质瘤总体生存的独立预后因素。 GSVA 揭示了 GJC1 影响神经胶质瘤细胞周期调节的潜在机制。最后，观察到GJC1表达与多种抗癌药物的敏感性之间存在显着相关性。这些发现证实了GJC1作为一种新型生物标志物，并为非神经元细胞中差异基因表达以及细胞周期对胶质瘤的影响提供了见解。 。因此，GJC1可用于预测胶质瘤预后并具有潜在的治疗价值。版权所有©2024 Ji，Chen，Lin，Ma，Yang，Zhao，Chen and Yang。

Gliomas, originating from the most common non-neuronal cells in the brain (glial cells), are the most common brain tumors and are associated with high mortality and poor prognosis. Glioma cells exhibit a tendency to disrupt normal cell-cycle regulation, leading to abnormal proliferation and malignant growth. This study investigated the predictive potential of GJC1 in gliomas and explored its relationship with the cell cycle.Retrospective analysis of RNA-seq and single-cell sequencing data was conducted using the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) databases. The differential expression of GJC1 in gliomas with various pathological features and in different non-neuronal cell groups was analyzed. Functional data were examined using gene set variation analysis (GSVA). Furthermore, CellMiner was used to evaluate the relationship between GJC1 expression and predicted treatment response across these databases.GJC1 expression was enriched in high-grade gliomas and 1p/19q non-codeletion gliomas. GJC1 enrichment was observed in classical and mesenchymal subtypes within the TCGA glioma subtype group. In single-cell subgroup analysis, GJC1 expression was higher in glioma tissues compared to other non-neuronal cells. Additionally, the TCGA classical subtype of glioma cells exhibited more GJC1 expression than the other subgroups. GJC1 emerged as an independent prognostic factor for overall survival in glioma. GSVA unveiled potential mechanisms by which GJC1 may impact cell-cycle regulation in glioma. Finally, a significant correlation was observed between GJC1 expression and the sensitivity of multiple anti-cancer drugs.These findings confirmed GJC1 as a novel biomarker and provided insights into the differential gene expression in non-neuronal cells and the impact of the cell cycle on gliomas. Consequently, GJC1 may be used to predict glioma prognosis and has potential therapeutic value.Copyright © 2024 Ji, Chen, Lin, Ma, Yang, Zhao, Chen and Yang.